Categories: News

AutoFlight V5000 Matrix Concludes ‘Heterogeneous Three-Aircraft Formation’ Flight, Officially Kicks Off Airworthiness Certification

KUNSHAN, China, May 24, 2026 /PRNewswire/ — AutoFlight has successfully completed a demonstration flight of a heterogeneous three-aircraft formation, consisting of one V5000 Matrix and two V2000-series eVTOL aircraft. The mission has validated key capabilities including communication links, route planning, flight coordination and safety control across 5-ton and 2-ton platforms. It also demonstrates AutoFlight’s system integration and multi-aircraft coordinated operations in low-altitude logistics, emergency response, maritime support, and regional air transport networks.

- Advertisement -

https://www.youtube.com/watch?v=1XRAzieNRTE

- Advertisement -

As a flagship in AutoFlight’s “From Small to Big, From Cargo to Passengers” product portfolio, the V5000 Matrix is designed for heavy-lift, long-range and point-to-point high-value missions. Following its transition flight in February 2026, the cargo hybrid-electric variant V5000CGH has officially entered airworthiness certification, moving from R&D validation to a standardized airworthiness approval process.

- Advertisement -

The V5000CGH features a 5,700 kg maximum takeoff weight, 1.5-ton payload, 14 m³ cargo hold (for two AKE containers), a cruise speed of 280 km/h and a 1,500 km range. It breaks through limits of payload, range and cost, expanding eVTOL applications into long-haul, heavy-duty logistics.

- Advertisement -

Furthermore, the V5000CGH supports large-scale emergency rescue, offshore energy supply and inter-provincial heavy feeder logistics, upgrading traditional slow delivery to fast, flexible low-altitude transport.

- Advertisement -

AutoFlight upholds a safety-first, regulation-driven approach. Its airworthiness team brings experience from ARJ21-700, C919 and Diamond DA42 programs. AutoFlight’s V2000CG CarryAll has obtained CAAC’s full airworthiness certificates (TC, PC, AC), while the V2000EM Prosperity is in compliance demonstration.

- Advertisement -

AutoFlight will continue strict airworthiness compliance to accelerate V5000CGH testing, flight trials and certification, advancing heavy-payload long-range eVTOL into commercial use and building sustainable low-altitude logistics infrastructure.

- Advertisement -

Video – https://mma.prnewswire.com/media/2986599/V5000_Matrix.mp4
Photo – https://mma.prnewswire.com/media/2986598/image1.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/autoflight-v5000-matrix-concludes-heterogeneous-three-aircraft-formation-flight-officially-kicks-off-airworthiness-certification-302780777.html

- Advertisement -

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

11 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

11 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

11 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

13 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

14 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

14 hours ago